ATE437963T1 - In-vitro verfahren zum nachweis eines übergangszellkarzinoms der blase - Google Patents
In-vitro verfahren zum nachweis eines übergangszellkarzinoms der blaseInfo
- Publication number
- ATE437963T1 ATE437963T1 AT04723215T AT04723215T ATE437963T1 AT E437963 T1 ATE437963 T1 AT E437963T1 AT 04723215 T AT04723215 T AT 04723215T AT 04723215 T AT04723215 T AT 04723215T AT E437963 T1 ATE437963 T1 AT E437963T1
- Authority
- AT
- Austria
- Prior art keywords
- cell carcinoma
- vitro method
- transitional cell
- bladder
- cancer
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200300708 | 2003-03-26 | ||
| PCT/EP2004/003219 WO2004085676A1 (en) | 2003-03-26 | 2004-03-25 | In vitro method to detect bladder transitional cell carcinoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE437963T1 true ATE437963T1 (de) | 2009-08-15 |
Family
ID=33041266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04723215T ATE437963T1 (de) | 2003-03-26 | 2004-03-25 | In-vitro verfahren zum nachweis eines übergangszellkarzinoms der blase |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8124331B2 (de) |
| EP (1) | EP1611252B1 (de) |
| AT (1) | ATE437963T1 (de) |
| DE (1) | DE602004022266D1 (de) |
| DK (1) | DK1611252T3 (de) |
| ES (1) | ES2330634T3 (de) |
| WO (1) | WO2004085676A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| US9089601B2 (en) | 2006-07-10 | 2015-07-28 | University Of Rochester | Pre- and intra-operative imaging of bladder cancer |
| RU2321856C1 (ru) * | 2006-12-12 | 2008-04-10 | Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" | Способ диагностики поверхностных переходноклеточных карцином мочевого пузыря |
| ES2323927B1 (es) * | 2007-03-30 | 2010-05-14 | Laboratorios Salvat, S.A. | Metodo in vitro no invasivo para detectar carcinoma transicional de vejiga. |
| US8187601B2 (en) * | 2008-07-01 | 2012-05-29 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (FGFR3) binding proteins |
| EP3702371B1 (de) | 2009-03-25 | 2022-11-02 | Genentech, Inc. | Anti-fgfr3-antikörper und verfahren damit |
| WO2014018841A1 (en) * | 2012-07-27 | 2014-01-30 | Genentech, Inc. | Methods of treating fgfr3 related conditions |
| SG11201502455TA (en) * | 2012-09-27 | 2015-05-28 | Chugai Pharmaceutical Co Ltd | Fgfr3 fusion gene and pharmaceutical drug targeting same |
| UA122564C2 (uk) * | 2014-09-26 | 2020-12-10 | Янссен Фармацевтика Нв | Використання панелі мутантних генів fgfr для ідентифікації пацієнтів із раковим захворюванням, які піддаються лікуванню інгібітором fgfr |
| JP2019528460A (ja) | 2016-08-05 | 2019-10-10 | ザ・リサーチ・ファウンデーション・フォー・ザ・ステイト・ユニヴァーシティ・オブ・ニューヨーク | 膀胱がんのバイオマーカーとしてのケラチン17 |
| AU2021327387A1 (en) | 2020-08-21 | 2023-05-04 | Genzyme Corporation | Fgfr3 antibodies and methods of use |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030087854A1 (en) * | 2001-09-10 | 2003-05-08 | Isis Pharmaceuticals Inc. | Antisense modulation of fibroblast growth factor receptor 3 expression |
| AU5214500A (en) | 1999-05-05 | 2000-11-21 | Centre National De La Recherche Scientifique (C.N.R.S.) | Means for detecting and treating pathologies linked to fgfr3 |
| CA2450793A1 (en) | 2001-06-20 | 2002-12-27 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
-
2004
- 2004-03-25 AT AT04723215T patent/ATE437963T1/de not_active IP Right Cessation
- 2004-03-25 EP EP04723215A patent/EP1611252B1/de not_active Expired - Lifetime
- 2004-03-25 DK DK04723215T patent/DK1611252T3/da active
- 2004-03-25 WO PCT/EP2004/003219 patent/WO2004085676A1/en not_active Ceased
- 2004-03-25 ES ES04723215T patent/ES2330634T3/es not_active Expired - Lifetime
- 2004-03-25 DE DE602004022266T patent/DE602004022266D1/de not_active Expired - Lifetime
- 2004-03-25 US US10/550,608 patent/US8124331B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK1611252T3 (da) | 2009-11-23 |
| US20070092878A1 (en) | 2007-04-26 |
| ES2330634T3 (es) | 2009-12-14 |
| WO2004085676A1 (en) | 2004-10-07 |
| EP1611252A1 (de) | 2006-01-04 |
| EP1611252B1 (de) | 2009-07-29 |
| US8124331B2 (en) | 2012-02-28 |
| DE602004022266D1 (de) | 2009-09-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sottnik et al. | Tumor-induced pressure in the bone microenvironment causes osteocytes to promote the growth of prostate cancer bone metastases | |
| Bellamri et al. | Alteration of human macrophage phenotypes by the anti-fibrotic drug nintedanib | |
| Gu et al. | MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells | |
| Louboutin et al. | Blood‐brain barrier abnormalities caused by HIV‐1 gp120: Mechanistic and therapeutic implications | |
| EP3112476A3 (de) | Verfahren, zusammensetzungen, verwendungen und kits für vitamin-d-mangel und verwandten erkrankungen | |
| BR0308290A (pt) | Tratamento e prevenção de distúrbios inflamatórios | |
| NO20044462L (no) | Anvendelse av EP4-reseptorligander i behandling av IL-6 involverte sykdommer | |
| Liu et al. | Ursodeoxycholic acid attenuates acute aortic dissection formation in angiotensin II-infused apolipoprotein E-deficient mice associated with reduced ROS and increased Nrf2 levels | |
| BRPI0810336A2 (pt) | "método para tratar e/ou prevenir úlceras de pele em um indivíduo" | |
| ATE437963T1 (de) | In-vitro verfahren zum nachweis eines übergangszellkarzinoms der blase | |
| CY1118566T1 (el) | Διαγνωση με χρηση ιντερφερονης τυπου 1 | |
| AR060306A1 (es) | Terapia de combinacion de anticuerpos contra ctla4 | |
| SG146653A1 (en) | Methods and reagents for the treatment of immunoinflammatory disorders | |
| ATE263371T1 (de) | Therapeutisches agenz mit quantitativem verbrauchsmarker und methode zum nachweis des agenzverbrauchs | |
| MX2011006091A (es) | Inhibidores de imidazopirazina syk. | |
| BR9914648A (pt) | Processo para monitorar ação medicamentosa deinibidor de proteasoma | |
| Suneetha | Role of dimethyl fumarate in oxidative stress of multiple sclerosis: A review | |
| ATE511645T1 (de) | Testverfahren zum nachweis von antikörpern gegen lysosomenenzyme | |
| WO2020176654A8 (en) | Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents | |
| Fujita et al. | X‐ray irradiation and Rho‐kinase inhibitor additively induce invasiveness of the cells of the pancreatic cancer line, MIAPaCa‐2, which exhibits mesenchymal and amoeboid motility | |
| Bui et al. | Effects of CYP3A modulators on the pharmacokinetics of naloxegol | |
| DE60125417D1 (de) | Verminderung der nebenwirkungen der chemotherapie in krebspatienten | |
| BRPI0507958A (pt) | biomarcadores | |
| PL1889920T3 (pl) | Sposób identyfikacji związków do terapii antynowotworowej in vitro | |
| Wu et al. | Glycine tomentella hayata extract and its ingredient daidzin ameliorate cyclophosphamide-induced hemorrhagic cystitis and oxidative stress through the action of antioxidation, anti-fibrosis, and anti-inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |